CEO & Managing Director’s Message

As Managing Director and Chief Executive Officer, my focus remains clear: to build an institution that is resilient, scalable, and prepared for long-term leadership in an evolving healthcare landscape. Our ambition is not only to grow, but to grow responsibly, with discipline in execution, strength in governance, and clarity in direction.

The year was one of disciplined prioritization. We concentrated on reinforcing the structural foundations of the business, ensuring that our next phase of expansion is supported by robust systems, strong governance, and operational excellence.

We continued shaping Avalon Pharma into a more diversified and specialty-oriented pharmaceutical platform. This evolution reflects deliberate choices, positioning the Company to participate in higher-value therapeutic segments aligned with national healthcare priorities and regional demand.

At the same time, we strengthened the backbone of performance. Operational excellence, quality discipline, financial discipline, and supply chain resilience remain central to our strategy. The improvements embedded across our systems are structural in nature, enabling sustainable growth while protecting margins and maintaining regulatory rigor.

A defining pillar of our long-term success is human capital. Through structured talent development and continuous learning, we are institutionalizing knowledge, empowering Saudi talent, and building leadership depth capable of carrying Avalon Pharma forward into the next decade.

Equally important is culture. We continue to cultivate a performance-driven, values-based environment built on accountability, agility, and opportunity. This cultural strength is not a soft asset, it is a strategic advantage that supports execution, innovation, and long-term sustainability.

Looking ahead, our priorities remain focused and disciplined. We will continue deepening our presence in specialty and advanced therapies, strengthening our manufacturing and localization capabilities, and expanding regionally with prudence and strategic alignment. At the same time, we remain committed to further institutionalizing governance, developing talent, and advancing operational excellence to support sustainable long-term growth.

Avalon Pharma’s journey is long-term by design. We are building not only for today’s performance, but for tomorrow’s relevance and leadership, aligned with the Kingdom’s ambitions and prepared for the opportunities that lie ahead.

On behalf of the Executive Management Team, I extend my sincere appreciation to our Board of Directors for their continued guidance, to our employees for their dedication, and to our shareholders and partners for their trust and confidence.

With discipline, ambition, and clarity of purpose, we move confidently toward 2030 and beyond